Abstract
Results suggest that the combination of bevacizumab plus temozolomide is active in terms of response rate, survival, performance, quality of life, and cognition in elderly patients with glioblastoma multiforme with poor performance status.Whether this combination is superior to temozolomide alone remains to be demonstrated by a randomized study. The optimal treatment of glioblastoma multiforme (GBM) in patients aged ≥70 years with a Karnofsky performance status (KPS) <70 is not established. This clinical trial evaluated the efficacy and safety of upfront temozolomide (TMZ) and bevacizumab (Bev) in patients aged ≥70 years and a KPS <70. Patients aged ≥70 years with a KPS <70 and biopsy-proven GBM were eligible for this multicenter, prospective, nonrandomized, phase II trial of older patients with impaired performance status. Treatment consisted of TMZ administered at 130-150 mg/m2 per day for 5 days every 4 weeks plus Bev administered at 10 mg/kg every 2 weeks. The trial included 66 patients (median age of 76 years; median KPS of 60). The median overall survival (OS) was 23.9 weeks (95% confidence interval [CI], 19-27.6), and the median progression-free survival (PFS) was 15.3 weeks (95% CI, 12.9-19.3). Twenty-two (33%) patients...Continue Reading
References
Mar 15, 1997·Cancer·A FleuryJ Y Delattre
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Apr 13, 2007·The New England Journal of Medicine·Florence Keime-GuibertUNKNOWN Association of French-Speaking Neuro-Oncologists
Sep 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Henry S FriedmanTimothy Cloughesy
Jun 29, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jaime Gállego Pérez-LarrayaJean-Yves Delattre
Apr 21, 2012·Cancer·Jacob G ScottFabio M Iwamoto
May 15, 2012·The Lancet Oncology·Wolfgang WickUNKNOWN NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer Society
Aug 11, 2012·The Lancet Oncology·Annika MalmströmUNKNOWN Nordic Clinical Brain Tumour Study Group (NCBTSG)
Nov 1, 2012·Neuro-oncology·Therese A DolecekCarol Kruchko
May 2, 2013·Cancer Medicine·Emil LouJames J Vredenburgh
Feb 21, 2014·The New England Journal of Medicine·Mark R GilbertMinesh P Mehta
Feb 21, 2014·The New England Journal of Medicine·Olivier L ChinotTimothy Cloughesy
Apr 12, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B ChauffertO Chinot
Jul 19, 2014·The Lancet Oncology·Walter TaalMartin J van den Bent
Sep 11, 2014·Drugs·Laurence Fardet, Bruno Fève
Sep 24, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wilson RoaElena Fidarova
Jul 1, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B ChauffertO Chinot
Citations
Mar 24, 2020·The Cochrane Database of Systematic Reviews·Catherine HannaRobin Grant
Aug 6, 2020·Oncogene·Lin QiXing-Ding Zhang
May 26, 2018·International Journal of Clinical Oncology·Ken-Ichiro MatsudaYukihiko Sonoda
Apr 16, 2020·Cancers·Vilashini RajaratnamShama Parveen Mirza
Mar 13, 2019·Cancers·Giuseppe MinnitiSergio Paolini
Oct 14, 2020·Cell Biology International·S Daisy PrecillaAnitha Thirugnanasambandhar Sivasubramanian
Jan 20, 2021·The Journal of Clinical Investigation·Rohit SharmaVamsi K Mootha
Jan 21, 2021·BMC Cancer·Jieqiong WenPengbo Zhang
Nov 21, 2020·Journal of Neuro-oncology·Christopher FarrellJeffrey J Olson
Dec 20, 2020·Pharmaceuticals·Yusuke FunakoshiMasahiro Mizoguchi
Nov 21, 2020·Journal of Neuro-oncology·Navid RedjalJeffrey J Olson
Mar 23, 2021·Frontiers in Physiology·Joris GuyonThomas Daubon
May 1, 2021·Cancers·Elisabete Cruz Da SilvaLaurence Choulier
Jul 3, 2021·Pharmaceuticals·Julie BolcaenCharlot Vandevoorde
Jul 20, 2021·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Hui YaoYulun Huang
Apr 21, 2020·Revue neurologique·F Laigle-Donadey, S Greffard